Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Tamara Kempter, Joachim B. Kunz, Paulina Richter-Pechanska, Katarzyna Tomska, Tobias Rausch, Busra Erarslan-Uysal, Cornelia Eckert, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Gunnar Cario, Gabriele Escherich, Renate Kirschner-Schwabe, Martina U. Muckenthaler, Jan O. Korbel, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 1315.

https://doi.org/10.1182/blood-2021-148420

Published: 2021

Journal Articles

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

Malwine J. Barz, Jana Hof, Stefanie Groeneveld-Krentz, Jui Wan Loh, Annabell Szymansky, Kathy Astrahantseff, Arend von Stackelberg, Hossein Khiabanian, Adolfo A. Ferrando, Cornelia Eckert, Renate Kirschner-Schwabe

Blood (2020) 135 (12): 921–933.

https://doi.org/10.1182/blood.2019002499

Published: 2020

Includes: Supplemental data

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

Clonal Evolution Mechanisms and Collateral Sensitivity to Impdh Inhibitor Therapy in Relapsed Lymphoblastic Leukemia

Chelsea Dieck, Gannie Tzoneva, PhD, Koichi Oshima, MD PhD, Alberto Ambesi-Impiombato, Marta Sanchez-Martin, PhD, Maria Luisa Sulis, MD, Motohiro Kato, MD PhD, Katsuyoshi Koh, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD, Julie M. Gastier-Foster, PhD, Mignon L. Loh, MD, Renate Kirschner-Schwabe, PhD, Chioma Madubata, Raul Rabadan, Adolfo A. Ferrando, MD PhD

Blood (2017) 130 (Supplement 1): 2602.

https://doi.org/10.1182/blood.V130.Suppl_1.2602.2602

Published: 2017

Journal Articles

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Blood (2017) 130 (Supplement 1): 2723.

https://doi.org/10.1182/blood.V130.Suppl_1.2723.2723

Published: 2017

Journal Articles

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Blood (2017) 130 (Supplement 1): 2726.

https://doi.org/10.1182/blood.V130.Suppl_1.2726.2726

Published: 2017

Journal Articles

Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 4068.

https://doi.org/10.1182/blood.V128.22.4068.4068

Published: 2016

Journal Articles

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

Paulina Richter-Pechanska, PhD, Joachim B. Kunz, MD, Jana Hof, Martin Zimmermann, PhD, Tobias Rausch, PhD, Obul Reddy Bandapalli, PhD, Elena Orlova, Greta Scapinello, Judit Sagi, Martin Stanulla, MD, Martin Schrappe, MD PhD, Renate Kirschner-Schwabe, PhD, Cornelia Eckert, PhD, Vladimir Benes, PhD, Jan O. Korbel, PhD, Martina U. Muckenthaler, PhD, Andreas E Kulozik, MD PhD

Blood (2016) 128 (22): 1084.

https://doi.org/10.1182/blood.V128.22.1084.1084

Published: 2016

Journal Articles

Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations

Blood (2016) 128 (22): 453.

https://doi.org/10.1182/blood.V128.22.453.453

Published: 2016

Journal Articles

Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent

Paulina Pechanska, Joachim Kunz, MD, Tobias Rausch, Obul Reddy Bandapalli, PhD, Elena Orlova, Judit Sagi, Martin Stanulla, MD, Martin Schrappe, MD PhD, Renate Kirschner-Schwabe, PhD, Jana Hof, Cornelia Eckert, Rolf Köhler, Martina U. Muckenthaler, PhD, Jan o. Korbel, Andreas E Kulozik, MDPhD

Blood (2015) 126 (23): 1428.

https://doi.org/10.1182/blood.V126.23.1428.1428

Published: 2015

Journal Articles

De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL

Hui Li, PhD, Benshang Li, Fan Yang, Caiwen Duan, Yun Bai, Jun J Yang, PhD, Jing Chen, MD PhD, Arend von Stackelberg, MD, Hongzhuan Chen, PhD, JingYan Tang, MD, Adolfo A. Ferrando, MD PhD, Jinghui Zhang, PhD, Shengyue Wang, Renate Kirschner-Schwabe, PhD, Bin-Bing S. Zhou, PhD

Blood (2015) 126 (23): 2627.

https://doi.org/10.1182/blood.V126.23.2627.2627

Published: 2015

Journal Articles

Clinical Significance of NT5C2 Mutations in Children with First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia

Jana Hof, MSc, Annabell Szymansky, MSc, Arend von Stackelberg, MD, Cornelia Eckert, PhD, Renate Kirschner-Schwabe, PhD

Blood (2014) 124 (21): 3789.

https://doi.org/10.1182/blood.V124.21.3789.3789

Published: 2014

Journal Articles

Targeted Deep Sequencing of Genetic Alterations Identified By Whole Exome Sequencing Reveals Clonal Evolution in Pediatric T-Lymphoblastic Leukemia

Blood (2014) 124 (21): 491.

https://doi.org/10.1182/blood.V124.21.491.491

Published: 2014

Journal Articles

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

Julie Irving, Elizabeth Matheson, Lynne Minto, Helen Blair, Marian Case, Christina Halsey, Isabella Swidenbank, Frida Ponthan, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Jana Hof, James Allan, Christine Harrison, Josef Vormoor, Arend von Stackelberg, Cornelia Eckert

Blood (2014) 124 (23): 3420–3430.

https://doi.org/10.1182/blood-2014-04-531871

Published: 2014

Includes: Supplemental data

Journal Articles

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

Julie Irving, PhD, Elizabeth C. Matheson, MPhil, Lynne Minto, Helen Blair, PhD, Marian Case, MSc, Christina Halsey, MD, PhD, Isabella Swidenbank, MRes, Frida Ponthan, PhD, Renate Kirschner-Schwabe, PhD, Stefanie Groeneveld-Krentz, MSc, Jana Hof, MSc, James Allan, PhD, Christine J. Harrison, PhD, Josef Vormoor, MD, Arend Stackelberg, MD, Cornelia Eckert, PhD

Blood (2013) 122 (21): 823.

https://doi.org/10.1182/blood.V122.21.823.823

Published: 2013

Journal Articles

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

Peter Rhein, PhD, Rita Mitlohner, Renate Kirschner-Schwabe, PhD, Christian Hagemeier, MD, PhD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Iduna Fichtner, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, Leonid Karawajew, PhD

Blood (2011) 118 (21): 752.

https://doi.org/10.1182/blood.V118.21.752.752

Published: 2011

Journal Articles

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 1718.

https://doi.org/10.1182/blood.V116.21.1718.1718

Published: 2010

Journal Articles

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, Richard Ratei

Blood (2010) 115 (18): 3763–3771.

https://doi.org/10.1182/blood-2009-10-247585

Published: 2010

Journal Articles

Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 .

Cornelia Eckert, Rolf Koehler, Thomas Flohr, Nikola Hagedorn, Anja Moericke, Martin Stanulla, Renate Kirschner-Schwabe, Gunnar Cario, Arend von Stackelberg, Claus R Bartram, Guenter Henze, Martin Schrappe, Andre Schrauder

Blood (2009) 114 (22): 2612.

https://doi.org/10.1182/blood.V114.22.2612.2612

Published: 2009

NARROW

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Clonal Evolution Mechanisms and Collateral Sensitivity to Impdh Inhibitor Therapy in Relapsed Lymphoblastic Leukemia

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations

Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent

De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL

Clinical Significance of NT5C2 Mutations in Children with First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia

Targeted Deep Sequencing of Genetic Alterations Identified By Whole Exome Sequencing Reveals Clonal Evolution in Pediatric T-Lymphoblastic Leukemia

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only